[1]Torre LA, Siegel RL, Waed EM, et al. Global cancer incidence and mortality rates and trends-an update[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25: 16-27. [2]Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, doi: 10.3322/caac.21660. [3]Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer[J]. Nat Rev Cancer, 2005, 5: 761-772. [4]Sanchez J, Carter TR, Cohen MS, et al. Old and new approaches to target the Hsp90 chaperone[J]. Curr Cancer Drug Targets, 2020, 20: 253-270. [5]Jackson SE. Hsp90: structure and function[J]. Top Curr Chem, 2013, 328:155-240. [6]Yuno A, Lee MJ, Lee S, et al. Clinical evaluation and biomarker profiling of Hsp90 inhibitors[J]. Methods Mol Biol, 2018, 1709: 423-441. [7]Eustace BK, SAKURAI T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness[J]. Nat Cell Biol, 2004, 6: 507-514. [8]Sidera K, Gaitanou M, Stellas D, et al. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2[J]. J Biol Chem, 2008, 283: 2031-2041. [9]Liu X, Yan Z, Huang L, et al. Cell surface heat shock protein 90 modulates prostate cancer cell adhesion and invasion through the integrin-β1/focal adhesion kinase/c-Src signaling pathway[J]. Oncol Rep, 2011, 25: 1343-1351. [10]Jiang Y, Yang N, Zhang H, et al. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition[J]. J Control Release, 2016, 221: 26-36. |